Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rajiv Mehta

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Annals of the Rheumatic Diseases|May 3, 2023
Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studiesWalter Reinisch, Wayne Hellstrom, Radboud J E M Dolhain, et al.
The Lancet. Gastroenterology & Hepatology|December 5, 2024
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trialSéverine Vermeire, Stefan Schreiber, David T Rubin, et al.
Digestive Diseases and Sciences|October 17, 2018
Correction to: Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 AnalysisSang Hoon Ahn, Patrick Marcellin, Xiaoli Ma, et al.
Digestive Diseases and Sciences|August 24, 2018
Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 AnalysisSang Hoon Ahn, Patrick Marcellin, Xiaoli Ma, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trialMaria Buti, Edward Gane, Wai Kay Seto, et al.
Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology|November 16, 2016
Chronic hepatitis C virus infection in India: Regional demographics and distribution of viral genotypesSamir R Shah, P N Rao, Shiv K Sarin, et al.
Metabolic Syndrome and Related Disorders|January 27, 2022
Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver DiseaseAjay Duseja, Shivaram P Singh, Manu Mehta, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trialHenry L Y Chan, Scott Fung, Wai Kay Seto, et al.
Lancet (London, England)|June 6, 2021
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trialBrian G Feagan, Silvio Danese, Edward V Loftus, et al.
Gastroenterology|October 11, 2015
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis BPatrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Annals of the Rheumatic Diseases|May 3, 2023
Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studiesWalter Reinisch, Wayne Hellstrom, Radboud J E M Dolhain, et al.
The Lancet. Gastroenterology & Hepatology|December 5, 2024
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trialSéverine Vermeire, Stefan Schreiber, David T Rubin, et al.
Digestive Diseases and Sciences|October 17, 2018
Correction to: Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 AnalysisSang Hoon Ahn, Patrick Marcellin, Xiaoli Ma, et al.
Digestive Diseases and Sciences|August 24, 2018
Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 AnalysisSang Hoon Ahn, Patrick Marcellin, Xiaoli Ma, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trialMaria Buti, Edward Gane, Wai Kay Seto, et al.
Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology|November 16, 2016
Chronic hepatitis C virus infection in India: Regional demographics and distribution of viral genotypesSamir R Shah, P N Rao, Shiv K Sarin, et al.
Metabolic Syndrome and Related Disorders|January 27, 2022
Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver DiseaseAjay Duseja, Shivaram P Singh, Manu Mehta, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trialHenry L Y Chan, Scott Fung, Wai Kay Seto, et al.
Lancet (London, England)|June 6, 2021
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trialBrian G Feagan, Silvio Danese, Edward V Loftus, et al.
Gastroenterology|October 11, 2015
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis BPatrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, et al.
Pageof 5